FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3039096369> ?p ?o ?g. }

• W3039096369 endingPage "77" @default.
• W3039096369 startingPage "69" @default.
• W3039096369 abstract "Objective The current literature on the major complications of embolo-sclerotherapy of upper and lower extremity vascular malformations is scarce. Evaluating and understanding the rates and types of potential major complications of embolo-sclerotherapy of vascular malformations help treatment planning and informed consent. Therefore, this study reviewed major complications following embolo-sclerotherapy of all upper and lower extremity vascular malformations in a single specialized multidisciplinary vascular malformation center over a 5-year period. Methods All patients with vascular malformations underwent multidisciplinary directed intervention. Demographic, procedural, follow-up, and complication data were collected prospectively in a dedicated database, and reviewed retrospectively. Major complications for upper and lower extremity vascular malformations from 1 January 2013 to 31 December 2017 were analyzed. All embolo-sclerotherapies of high-flow vascular malformations (HFVMs) were performed under selective catheter angiography and direct injection, but low-flow vascular malformations (LFVM) with direct injection only. Major complications were defined as any tissue or functional damage caused by direct injection, distal embolization, or tissue reaction. Results Seventy patients (median age of 25 years; 44 males and 26 females) had 150 embolo-sclerotherapy procedures for upper extremity vascular malformation. Of these, 28 patients had embolo-sclerotherapy for HFVM and 42 patients for LFVM; total 78 and 72 procedures, respectively. A total of 107 patients (median age of 26 years; 42 males and 65 females) had 160 embolo-sclerotherapy interventions for lower extremity vascular malformations. Of these, 18 patients had embolo-sclerotherapy for HFVM and 89 patients for LFVM; total of 30 and 130 procedures, respectively. The overall major complication rates following embolo-sclerotherapy of upper and lower extremity vascular malformations were 14.3% and 4.7%, respectively ( P = 0.030). In the upper extremity HFVM group, major complications from embolo-sclerotherapy occurred in five patients; three ischemic fingers requiring amputation and two skin ulcerations. Meanwhile, in the upper extremity LFVM group, major complications occurred in five patients; one median nerve injury requiring nerve grafting and hand therapy, one hand contracture requiring tendon release, and three skin ulcerations. There was only one major complication, which was cellulitis in the lower extremity HFVM group. In the lower extremity LFVM group, major complications occurred in four patients; two skin ulcerations, one cellulitis, and one deep vein thrombosis. Conclusions Embolo-sclerotherapy is relatively safe for upper and lower extremity vascular malformations in a high-volume experienced center where our major complication rates were 14.3% and 4.7%, respectively, which compare favorably or similar to those reported in most recent literature. These outcomes will direct treatment strategies to avoid local and systemic toxic complications in the upper and lower extremity, for both HFVM and LFVM, and to improve informed consent." @default.
• W3039096369 created "2020-07-10" @default.
• W3039096369 creator A5039339873 @default.
• W3039096369 creator A5049508621 @default.
• W3039096369 creator A5061203219 @default.
• W3039096369 creator A5064877301 @default.
• W3039096369 creator A5075430054 @default.
• W3039096369 creator A5077725238 @default.
• W3039096369 creator A5085770549 @default.
• W3039096369 creator A5087589184 @default.
• W3039096369 date "2020-07-01" @default.
• W3039096369 modified "2023-09-27" @default.
• W3039096369 title "Incidence of major complication following embolo-sclerotherapy for upper and lower extremity vascular malformations" @default.
• W3039096369 cites W2012287105 @default.
• W3039096369 cites W2015199038 @default.
• W3039096369 cites W2015768650 @default.
• W3039096369 cites W2035713065 @default.
• W3039096369 cites W2047770943 @default.
• W3039096369 cites W2052750800 @default.
• W3039096369 cites W2059349437 @default.
• W3039096369 cites W2081245133 @default.
• W3039096369 cites W2115695634 @default.
• W3039096369 cites W2131291214 @default.
• W3039096369 cites W2150652499 @default.
• W3039096369 cites W2169839613 @default.
• W3039096369 cites W2569146241 @default.
• W3039096369 cites W2793142012 @default.
• W3039096369 cites W2805622020 @default.
• W3039096369 cites W2923887856 @default.
• W3039096369 cites W4241731184 @default.
• W3039096369 doi "https://doi.org/10.1177/1708538120937616" @default.
• W3039096369 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32605532" @default.
• W3039096369 hasPublicationYear "2020" @default.
• W3039096369 type Work @default.
• W3039096369 sameAs 3039096369 @default.
• W3039096369 citedByCount "6" @default.
• W3039096369 countsByYear W30390963692021 @default.
• W3039096369 countsByYear W30390963692022 @default.
• W3039096369 countsByYear W30390963692023 @default.
• W3039096369 crossrefType "journal-article" @default.
• W3039096369 hasAuthorship W3039096369A5039339873 @default.
• W3039096369 hasAuthorship W3039096369A5049508621 @default.
• W3039096369 hasAuthorship W3039096369A5061203219 @default.
• W3039096369 hasAuthorship W3039096369A5064877301 @default.
• W3039096369 hasAuthorship W3039096369A5075430054 @default.
• W3039096369 hasAuthorship W3039096369A5077725238 @default.
• W3039096369 hasAuthorship W3039096369A5085770549 @default.
• W3039096369 hasAuthorship W3039096369A5087589184 @default.
• W3039096369 hasBestOaLocation W30390963692 @default.
• W3039096369 hasConcept C120665830 @default.
• W3039096369 hasConcept C121332964 @default.
• W3039096369 hasConcept C141071460 @default.
• W3039096369 hasConcept C2776035437 @default.
• W3039096369 hasConcept C2777466421 @default.
• W3039096369 hasConcept C2777507709 @default.
• W3039096369 hasConcept C2778230777 @default.
• W3039096369 hasConcept C2780073493 @default.
• W3039096369 hasConcept C61511704 @default.
• W3039096369 hasConcept C71924100 @default.
• W3039096369 hasConcept C81182388 @default.
• W3039096369 hasConceptScore W3039096369C120665830 @default.
• W3039096369 hasConceptScore W3039096369C121332964 @default.
• W3039096369 hasConceptScore W3039096369C141071460 @default.
• W3039096369 hasConceptScore W3039096369C2776035437 @default.
• W3039096369 hasConceptScore W3039096369C2777466421 @default.
• W3039096369 hasConceptScore W3039096369C2777507709 @default.
• W3039096369 hasConceptScore W3039096369C2778230777 @default.
• W3039096369 hasConceptScore W3039096369C2780073493 @default.
• W3039096369 hasConceptScore W3039096369C61511704 @default.
• W3039096369 hasConceptScore W3039096369C71924100 @default.
• W3039096369 hasConceptScore W3039096369C81182388 @default.
• W3039096369 hasIssue "1" @default.
• W3039096369 hasLocation W30390963691 @default.
• W3039096369 hasLocation W30390963692 @default.
• W3039096369 hasLocation W30390963693 @default.
• W3039096369 hasOpenAccess W3039096369 @default.
• W3039096369 hasPrimaryLocation W30390963691 @default.
• W3039096369 hasRelatedWork W2022116360 @default.
• W3039096369 hasRelatedWork W2091294634 @default.
• W3039096369 hasRelatedWork W2154362091 @default.
• W3039096369 hasRelatedWork W2157740692 @default.
• W3039096369 hasRelatedWork W2364503405 @default.
• W3039096369 hasRelatedWork W2474039552 @default.
• W3039096369 hasRelatedWork W2945124548 @default.
• W3039096369 hasRelatedWork W3039096369 @default.
• W3039096369 hasRelatedWork W62711790 @default.
• W3039096369 hasRelatedWork W2410664179 @default.
• W3039096369 hasVolume "29" @default.
• W3039096369 isParatext "false" @default.
• W3039096369 isRetracted "false" @default.
• W3039096369 magId "3039096369" @default.
• W3039096369 workType "article" @default.